Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells

Molecular Cancer Therapeutics

Volumn 8, Issue 3, 2009, Pages 521-532

  Zinner, Ralph G ^a   Barrett, Brittany L ^a   Popova, Elmira ^b   Damien, Paul ^c   Volgin, Andrei Y ^a   Gelovani, Juri G ^a   Lotan, Reuben ^a   Tran, Hai T ^a   Pisano, Claudio ^d   Mills, Gordon B ^a   Mao, Li ^a   Hong, Waun K ^a   Lippman, Scott M ^a   Miller, John H ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d Sigma Tau SpA   (Italy)

^e SANTA FE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 [3' (1 ADAMANTYL) 4' HYDROXYBIPHENYL 4 YL]ACRYLIC ACID; 5 AZA 2' DEOXYCYTIDINE; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ANISOMYCIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; DEGUELIN; FENRETINIDE; GEMCITABINE; IMATINIB; INDIRUBIN; LONAFARNIB; MX 33501; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; RAPAMYCIN; RETINOIC ACID; UNCLASSIFIED DRUG; VORINOSTAT; PRODRUG;

ALGORITHM; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CANCER SIZE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; LUNG TUMOR; METHODOLOGY; MOLECULAR WEIGHT; PATHOLOGY; TUMOR CELL CULTURE; VALIDATION STUDY;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; MOLECULAR WEIGHT; PRODRUGS; TUMOR CELLS, CULTURED;

EID: 66449107566     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0937     Document Type: Article

References (24)

1. Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355:2542-2550 (Pubitemid 44917502)
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use ofchemother apy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792 (Pubitemid 32222155)
3. Frei E III, Eder JP. Principles ofdose, schedule, and combination therapy. In: Holland JF, Bast RC, Morton DL, Frei E, Kufe DW, Weichselbaum RR, editors. Cancer medicine. Baltimore: Williams and Wilkins; 2006. p. 590-599
4. Goldie JH, Codman AJ. A mathematical model for relating the drug sensitivity oftumors to the spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733 (Pubitemid 10138923)
5. Chu E, DeVita VT, Jr. Principles ofcancer management: chemotherapy. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Cancer, principles and practice ofoncology. Philadelphia: Lippencott Williams & Wilkins; 2001. p. 289-306.
6. Bendell JC, George D, Nixon A, Yu D, Hurwitz H. Results ofa phase I study ofbevaci zumab (BV), everolimus (EV), and erlotinib (E) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2007;Abstract 3548.
7. Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin Cancer Res 2007;13:5232-5237 (Pubitemid 47510344)
8. Smith A. Screening for drug discovery: the leading question. Nature 2002;418:453-459 (Pubitemid 34826849)
9. Goodnow RA, Jr., Gillespie P. Hit and Lead identification: efficient practices for drug discovery. Prog Med Chem 2007;45:1-61.
10. Wadman M. The right combination. Nature 2006;439:390-401. (Pubitemid 43152812)
11. Holland JH. Adaptation in natural and artificial systems, 2nd ed. Ann Arbor: MIT Press; 1992.
12. Kirkpatrick S, Gelatt CD, Jr., Vecchi MP. Optimization by Simulated Annealing. Science 1983;220:671-680
13. Abbas HA. An evolutionary artificial neural networks approach for breast cancer diagnosis. ArtifIntell Med 2002;25:265-281 (Pubitemid 34586827)
14. Zheng B, Chang YH, Wang XH, Good WF. Feature selection for computerized mass detection in digitized mammograms by using a genetic algorithm. Acad Radiol 1999;6:327-332 (Pubitemid 32674954)
15. Wong PK, Yu F, Shahangian A, Cheng G, Sun R, Ho CM. Closed-loop control ofce llular functions using combinatory drugs guided by a stochastic search algorithm. Proc Natl Acad Sci U S A 2008;105:5105-5110
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul 1984;22:27-55.
17. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism ofTaxol, topotecan and cisplatin against teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-1524 (Pubitemid 24330215)
18. Fang HB, Ross DD, Sausville E, Tan M. Experimental design and interaction analysis ofcombina tion studies ofdrugs with log-linear dose responses. Stat Med 2008;27:3071-3083
19. Whang YM, Choi EJ, Seo JH. Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor β expression in head and neck squamous carcinoma (HNSCC) cells. Cancer Chemother Phamacol 2005;56:543-555 (Pubitemid 41549157)
20. Denlinger CE, Rundall BK, Jones DR. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation ofreactive oxygen species. J Thorac Cardiovasc Surg 2004;128:740-748 (Pubitemid 39388930)
21. Touma SE, Goldberg JS, Moench P. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res 2005;11:3558-3566 (Pubitemid 40627912)
22. Schelman WR, Kolesar J, Schell K, et al. A phase I study ofvorinostat in combination with bortezomib in refractory solid tumors. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S, 2007:3573.
23. Badros AZ, Philip S, Niesvizk R, et al. Grant Phase I trial ofvorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts). J Clin Oncol 2008;26:abstr 8548.
24. Costa A, Malone W, Perloff M, et al. Tolerability of the synthetic retinoid fenretinide (HPR). Eur J Cancer Clin Oncol 1989;25:805-808 (Pubitemid 19164323)